论文部分内容阅读
目的：观察巴曲抗栓酶对急性心肌梗死（ＡＭＩ）的疗效。方法：２４例ＡＭＩ病人（男性１８例，女性６例；年龄６９±ｓ９ａ），其中８８％为发病１２ｈ内入院。入院即刻给阿司匹林０．３ｇ，ｐｏ，ｑｄ×３ｄ，再改为０．１ｇ，ｐｏ，ｑｄ；入院即ｉｖ输注巴曲抗栓酶２０ＢＵ溶于０．９％氯化钠液１００ｍＬ，１ｈ内滴完，以后每隔１ｄ（即入院ｄ３，ｄ５）再用巴曲抗栓酶１０ＢＵ，１次。结果：冠状动脉再通率为５０％（６ｈ内入院者为６９％），住院病死率为１２％，未见出血等不良反应。用药后凝血因子Ｉ有显著降低。结论：巴曲抗栓酶治疗ＡＭＩ是安全有效的。
Objective: To observe the efficacy of batroxobin on acute myocardial infarction (AMI). Methods: Twenty-four patients with AMI (18 males and 6 females; age 69 ± s9a), of whom 88% were admitted within 12 hours of onset. Admission immediately to aspirin 0.3g, po, qd × 3d, and then changed to 0.1g, po, qd; admission iv infusion of batroxobin 20BU dissolved in 0.9% sodium chloride solution 100mL, within 1h Drip finished every 1d (ie admission d3, d5) and then use batroxobin 10BU, 1 time. Results: The recanalization rate of coronary artery was 50% (69% hospitalized within 6 hours), and the in-hospital mortality rate was 12%. No adverse reaction such as bleeding was found. After treatment, coagulation factor I was significantly reduced. Conclusion: Batroxobin is safe and effective in the treatment of AMI.